Logo
x

Search

Subscribe Now

EC approval

Insights+: EMA Marketing Authorization of New Drugs in August 2024

Insights+: EMA Marketing Authorization of New Drugs in August 2024

  • September 24, 2024
Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

  • August 23, 2021
Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

  • July 22, 2021
Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

  • July 22, 2021
Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

  • March 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.